Breaking News

Coave Therapeutics Strengthens Management Workforce with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Authorized

PARIS, Sept. 6, 2022 /PRNewswire/ — Coave Therapeutics (‘Coave’), a clinical-stage biotechnology firm centered on creating life-changing gene therapies for CNS (Central Nervous System) and eye illnesses, at present introduced the appointments of Catherine Mathis, PharmD, as Vice President Regulatory Affairs and Julien Berger, as Head of Authorized Affairs. Ms. Mathis will outline and oversee […]